Effects of genistein on the mammary gland proliferation of adult ovariectomised Wistar rats.
The effects of phytoestrogens on the female breast are discussed controversially. On the one hand, epidemiological and experimental data provide evidence that dietary phytoestrogens may prevent the development of breast cancer. On the other hand, in breast cancer cell lines and tumour models isoflavone phytoestrogens have been demonstrated to stimulate the growth of estrogen-dependent breast cancer cells. To further investigate the molecular effects of genistein (Gen) on the mammary gland, we treated non-tumour bearing, ovariectomised female Wistar rats with this phytoestrogen either subcutaneously (10 mg/kg body weight) or orally (100 and 200 mg/kg body weight) for 3 days. Estradiol (E(2), 0.004 mg/kg s. c.) and ethynylestradiol (EE, 0.1 mg/kg per os) served as reference compounds. In the breast tissue, mRNA and protein expression of the progesterone receptor (marker for estrogenicity) and PCNA (marker gene for proliferation) were examined by quantitative real-time PCR, Western blotting and immunohistochemistry; the uterotrophic response was assessed also. Treatment with Gen per os or s. c. results in a small but significant stimulation of the uterine wet weight. In the mammary gland, Gen stimulates the expression of progesterone receptor (PR) but, in contrast to E(2), the isoflavone does not stimulate the expression of PCNA. These findings resemble recent data demonstrating a differential ability of Gen to induce uterine gene expression and uterine proliferation. Our data indicate that in non-malignant breast tissue short-term administration of Gen, in contrast to more potent estrogens like E(2), does not induce proliferation. Chronic stimulation of proliferation is believed to be a key mechanism during the development of breast cancer. The limited ability of Gen to stimulate proliferation in this tissue could be an indication for a limited carcinogenic potency of Gen in the breast. In further investigations it is important to identify molecular differences between healthy and malignant breast tissue which may explain the different sensitivity towards Gen treatment.
Hertrampf
Torsten
T
Institut für Kreislaufforschung und Sportmedizin, Abt. Molekuläre und Zelluläre Sportmedizin, Deutsche Sporthochschule Köln, Köln, Germany.
Schmidt
Simone
S
Seibel
Jan
J
Laudenbach-Leschowsky
Ute
U
Degen
Gisela H
GH
Diel
Patrick
P
D000284:Administration, Oral; D000818:Animals; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects*; D005260:Female; D019833:Genistein / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D007150:Immunohistochemistry; D008321:Mammary Glands, Animal / Q000187:drug effects; D010052:Ovariectomy; D048789:Phytoestrogens / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D008517:Phytotherapy; D016133:Polymerase Chain Reaction; D018809:Proliferating Cell Nuclear Antigen / Q000187:drug effects; D012313:RNA / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D011980:Receptors, Progesterone / Q000187:drug effects; D014599:Uterus / Q000187:drug effects
D048789:Phytoestrogens; D018809:Proliferating Cell Nuclear Antigen; D011980:Receptors, Progesterone; D012313:RNA; D019833:Genistein